Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment reporting

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02799771Completed

HYPID (Pulmonary Hypertension in Interstitial Lung Disease) EXTENSION

Role: lead

NCT01501578Completed

Pulmonary Fibrosis and Telomerase Mutation Study

Role: lead

NCT01443598Completed

Pulmonary Hypertension in Interstitial Lung Disease

Role: lead

NCT00960895Completed

Pulmonary Hypertension in Lymphangioleiomyomatosis

Role: lead

All 4 trials loaded